HEPATIC IMPACT OF ETRASIMOD FOR TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTEGRATED SAFETY SUMMARY FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME

Miguel Regueiro  1     Severine Vermeire  2     David T. Rubin  3     Marla C. Dubinsky  4     Ailsa L Hart  5     Joseph Wu  6     Jesse Green  7     John C. Woolcott  7     Kenneth J. Gorelick  7     Aoibhinn McDonnell  8     Krisztina Lazin  9     Laurent Peyrin-Biroulet  10, 11    
1 Cleveland Clinic, Cleveland, United States
2 University Hospitals Leuven, Leuven, Belgium
3 University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, United States
4 Icahn School of Medicine at Mount Sinai, New York, United States
5 St Mark’s Hospital, London, United Kingdom
6 Pfizer Inc, Groton, United States
7 Pfizer Inc, Collegeville, United States
8 Pfizer Ltd, Sandwich, Kent, United Kingdom
9 Pfizer AG, Zürich, Switzerland
10 University of Lorraine, CHRU-Nancy, Nancy, France
11 University of Lorraine, Inserm, NGERE, Nancy, France

Topic
IBD

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing